KZA 0.00% 8.0¢ kazia therapeutics limited

VAL-083 updated results, page-10

  1. 856 Posts.
    lightbulb Created with Sketch. 356
    Actually, I was just calculating the results for Kintara's drug for their "head-to-head" trial with Kazia (VAL-083 adjuvant monotherapy), and it seems wrong. I tabulated all patient PFS data for those patients which have already progressed (21 patients) and got the following numbers:

    (patient number - approx. PFS in months)
    1 - 14.5
    2 - 14.2
    3 - 11.4
    4 - 10.8
    5 - 10.5
    6 - 10.2
    7 - 10
    8 - 9.2
    9 - 8.6
    10 - 8.5
    11 - 8.2 <------- median patient
    12 - 7.5
    13 - 7.2
    14 - 6.9
    15 - 6.6
    16 - 6.3
    17 - 5.9
    18 - 5.5
    19 - 5.5
    20 - 5.3
    21 - 4.6

    From these 21 patients, the median PFS is 8.2 months.

    Now, they had 6 other patients which hadn't progressed yet.

    1 - 14
    2 - 12.2
    3 - 10
    4 - 9.4
    5 - 5.5
    6 -4

    However, even if we assume they all live to be 100, the median PFS only goes to patient #8 above, which is 9.2 months. If patients #5 and #6 in this bottom set progress sooner than 8.2 months, then the median PFS will be 8.5 months. So, I think the range for mPFS for Kintara should be 8.5-9.2. I don't know how they got 10.
 
watchlist Created with Sketch. Add KZA (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.